6:59 PM
 | 
Sep 28, 2005
 |  BC Extra  |  Company News

Dr. Reddy's spins out Perlecan

RDY spun out Perlecan to develop therapeutics for endocrine and cardiovascular diseases. The newco takes with it four NCEs: DRF 10945, a non-fibrate, predominantly PPAR alpha agonist that has completed Phase I testing for dyslipidemia; RUS 3108,...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >